Alfred W. Sandrock, Jr., M.D., Ph.D. Appointed to Voyager Therapeutics’ Board of Directors and Newly Formed Executive Committee
03 févr. 2022 07h00 HE
|
Voyager Therapeutics, Inc.
Accomplished drug developer to help further long-term strategy, external scientific and business collaborations Robin Swartz promoted to chief operating officer CAMBRIDGE, Mass., Feb. ...
Voyager Therapeutics Announces Positive Preclinical Data from New Vectorized anti-HER2 Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting
19 nov. 2021 07h30 HE
|
Voyager Therapeutics, Inc.
Novel intravenous (IV) vectorized antibody approach designed to activate innate immune system, destroy metastatic breast cancer tumors, and inhibit tumor progression in CNS Proprietary...
Voyager Therapeutics to Present Preclinical Data from Vectorized Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting
16 nov. 2021 07h00 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus...
Voyager Therapeutics Reports Third Quarter 2021 Financial and Operating Results
02 nov. 2021 07h00 HE
|
Voyager Therapeutics, Inc.
License option agreement with Pfizer provides Voyager $30M up front and up to $600M in potential exercise fees and milestone payments plus royalties in exchange for access to TRACER™ novel capsids for...
Voyager Therapeutics Presents Positive Preclinical Data Supporting CNS-Directed GBA1 Gene Therapy at Virtual Congress of the European Society of Gene and Cell Therapy
20 oct. 2021 08h54 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus...
Voyager Therapeutics Announces License Option Agreement with Pfizer for Next-Generation TRACERᵀᴹ AAV Capsids to Enable Neurologic and Cardiovascular Gene Therapy Programs
06 oct. 2021 07h00 HE
|
Voyager Therapeutics, Inc.
Voyager receives $30 million up front with potential option exercise fees and milestone payments of up to $600 million plus product sales-based royalties Pfizer receives transgene-specific access to...
Voyager Therapeutics to Participate in Upcoming Investor Conferences
02 sept. 2021 17h08 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation platform technologies,...
Voyager Therapeutics to Participate in Upcoming Investor Conferences
10 août 2021 16h20 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation platform technologies,...
Voyager Therapeutics Transforms Pipeline and Increases Investment in Next-Generation TRACER™ AAV Capsid and Vectorized Antibody Platform Technologies
09 août 2021 07h00 HE
|
Voyager Therapeutics, Inc.
Proprietary AAV capsids to power second-generation efforts in Huntington’s disease and ALS, pre-clinical programs in spinal muscular atrophy and diseases linked to GBA1 mutations Increased platform...
Voyager Therapeutics Announces Strategic Shift and Leadership Transitions
19 mai 2021 16h01 HE
|
Voyager Therapeutics, Inc.
Company focusing on rapidly moving VY-HTT01 into clinical development for Huntington’s disease and maximizing opportunities created by TRACERTM gene therapy technology platform and next-generation...